dr-chris-dvorak-md-106-1440x784-2x
dr-chris-dvorak-md-106-320x320-2x

Christopher Dvorak

MD

Chief of the Pediatric Allergy, Immunology and Bone Marrow Transplant Division
Pediatric hematologist and oncologist
BMT researcher and Sherlock Holmes enthusiast

Dr. Christopher Dvorak is a specialist in pediatric blood disorders and stem cell transplantation for children. He is chief of the UCSF Pediatric Allergy, Immunology and Bone Marrow Transplantation Division. He has a special interest in pediatric cancer.

In his research, Dvorak studies methods to decrease relapse after stem cell transplants for childhood leukemia. His research also includes efforts to improve care during stem cell transplants, especially in the prevention and treatment of invasive fungal infections, and to improve outcomes after stem cell transplants for severe combined immunodeficiency disease (genetic disorders in which infants lack immune function).

Dvorak earned his medical degree at Vanderbilt University School of Medicine. He completed a residency in pediatrics as well as a fellowship in pediatric hematology, oncology and bone marrow transplant at Stanford Medicine. Prior to joining UCSF in 2007, he was a clinical instructor for Stanford Medicine in the pediatric stem cell transplantation division.

  • Education

    Vanderbilt University School of Medicine, 1998

  • Residencies

    Stanford Medicine, Pediatrics, 2001

  • Fellowships

    Stanford Medicine, Pediatric Hematology and Oncology, 2005

  • Board Certifications

    Pediatric Hematology-Oncology, American Board of Pediatrics

Bone marrow transplant is a complex procedure with significant risks. My passion is to make it so safe that anyone could have a successful transplant.

Related conditions

Related treatments

Clinics I work with

(1)

blood-and-marrow-transplant-clinic-320x320-2x 3

Blood & Marrow Transplant (BMT) Clinic

Blood & Marrow Transplant (BMT) Clinic

San Francisco / Oakland

Where I see patients (2)

Expand Map

    Selected research

    Decorative Caduceus

    JSP191 Antibody Targeting Conditioning in SCID Patients

    The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Staff superheroes

    It’s a bird. It’s a plane. It’s a window washer! Dressed as a superhero to clean and brighten your day.

    Share